Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C70792
http://purl.obolibrary.org/obo/NCIT_C70792
|
|---|---|
| Preferred Name | Ramucirumab |
| Definitions |
A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells. |
|---|---|
| label | Ramucirumab
|
| prefLabel | Ramucirumab
|
| Legacy Concept Name | Anti-VEGFR-2_Fully_Human_Monoclonal_Antibody_IMC-1121B
|
| in_subset |
See more
See less
|
| Preferred_Name | Ramucirumab
|
| Is_Value_For_GDC_Property | |
| Display_Name | Ramucirumab
|
| Maps_To | Ramucirumab
|
| PDQ_Open_Trial_Search_ID | 570535
|
| Has_Target | |
| UMLS_CUI | C2742502
|
| FDA_UNII_Code | D99YVK4L0X
|
| prefixIRI | NCIT:C70792
|
| Accepted_Therapeutic_Use_For | metastatic colorectal cancer (mCRC); advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma; hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥ 400 ng/mL
multicentric Castleman's disease (MCD)
|
| NCI_Drug_Dictionary_ID | 570535
|
| Contributing_Source |
CTRP
FDA
|
| subClassOf | |
| code | C70792
|
| type | |
| ALT_DEFINITION | A substance being studied in the treatment of breast cancer that has come back. It binds to receptors for a protein called vascular endothelial growth factor (VEGF). This keeps VEGF from binding to the receptors and may stop the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.
|
| PDQ_Closed_Trial_Search_ID | 570535
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| CAS_Registry | 947687-13-0
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |